Kratom & Sleep: What Do Users Report – and What Does Research Show? - Kratoein

Kratom and Sleep: Withdrawal, REM Sleep and the State of Research

Sleep is one of the topics most frequently discussed in connection with Mitragyna speciosa. The discussion is considerably broader than the evidence: controlled investigations into the sleep of people who use kratom are almost entirely absent. Three things, however, can be set out reliably – how the sleep-wake rhythm is regulated in the first place, what is known about insomnia as a documented withdrawal symptom, and why no general statements can be derived from self-reports. That is what this article covers.

The sleep-wake rhythm: two processes working together

Sleep is not a state that simply arrives; it is the result of two independent control loops. Sleep research has described them as the two-process model since Alexander Borbély's work of 1982.

Process S is homeostatic sleep pressure: the longer you stay awake, the stronger the need for sleep becomes. This pressure builds across the day and is discharged during sleep.

Process C is the circadian rhythm: an internal clock running on a roughly 24-hour cycle, independent of how long you have been awake. Its seat is the suprachiasmatic nucleus in the hypothalamus, a cluster of a few tens of thousands of neurones that receives light information via the optic nerve and adjusts its phase accordingly.

Sleep disturbances rarely arise from a single factor. Usually they come from these two processes drifting apart – as in shift work, jet lag or night-time light exposure.

Adenosine: the carrier of sleep pressure

Adenosine is a by-product of cellular energy metabolism. It is formed when ATP is consumed in nerve cells and accumulates in the brain during waking hours. Through the receptor subtypes A1 and A2A it dampens the activity of wake-promoting cell groups. During sleep adenosine is cleared again – which is why sleep pressure is low in the morning.

Caffeine is an antagonist at precisely these receptors: it occupies them without activating them, and the accumulated sleep pressure simply stops being reported. For the alkaloids of Mitragyna speciosa, a comparable direct binding to adenosine receptors is not described. Anyone drawing an analogy with caffeine is therefore drawing it without a pharmacological basis.

Serotonin and melatonin: the biochemistry of the night

Melatonin is the central signalling molecule of the circadian rhythm. It is produced in the pineal gland, and it is produced from serotonin: the amino acid tryptophan becomes 5-hydroxytryptophan and then serotonin, which the enzyme AANAT converts to N-acetylserotonin and finally to melatonin. Light falling on the retina suppresses this last step; darkness releases it. This is why melatonin levels rise during the evening and typically peak between two and four o'clock in the morning.

Melatonin is not a sedative and does not force sleep. It is a timing signal – it tells the body what time of day it is. For mitragynine, receptor binding studies have described interactions with serotonergic receptors. Such in vitro findings describe binding at isolated receptors; they are not a statement about what happens in a living organism, and certainly not about a person's melatonin balance.

The arousal system

Set against sleep pressure is an ascending arousal system working through several messengers: noradrenaline from the locus coeruleus, histamine from the tuberomammillary nucleus, acetylcholine from the basal forebrain and dopamine, which is linked to attention and drive. Above all of these sits orexin (also called hypocretin), a neuropeptide from the lateral hypothalamus that stabilises these systems. When the orexin system fails, narcolepsy results – proof of how much active work a stable waking state is, rather than merely the absence of sleep.

What happens during sleep: the stages

Sleep is not a uniform state. It is organised into cycles of roughly 90 minutes, four to six of which are completed per night. In the sleep laboratory the stages are distinguished by EEG (brain activity), EOG (eye movements) and EMG (muscle tone).

Stage	Share in adults	Characteristics
N1 – sleep onset	about 5 %	Transition from wakefulness, slow rolling eye movements, easily woken
N2 – stable light sleep	about 45 to 55 %	Sleep spindles and K-complexes in the EEG; the largest share of the night
N3 – deep sleep	about 15 to 20 %	Slow delta waves; concentrated in the first half of the night; the phase of physical recovery
REM – dreaming sleep	about 20 to 25 %	Rapid eye movements, active EEG, near-complete muscle atonia; increases towards morning

REM sleep (rapid eye movement) is the most important section for the subject of this article. The brain shows activity resembling wakefulness while the skeletal muscles, apart from the eyes and the respiratory muscles, are paralysed. REM sleep is associated with the consolidation of memory and the processing of emotional experience. One property is decisive, and it can be described as a backlog effect: if REM sleep is suppressed over a longer period, the body subsequently makes up for it disproportionately. This phenomenon is called REM rebound – and it explains a great deal of what the next section is about.

Insomnia in withdrawal: the best-documented finding

Of everything said about kratom and sleep, this is the only point with a consistent basis: insomnia – difficulty falling asleep and staying asleep – is among the regularly documented symptoms on stopping after prolonged, regular use. It appears in case reports in the clinical literature as well as in the large self-report surveys conducted among users since around 2018. It is also among the symptoms that persist longest.

Why sleep is affected

The pattern follows what is well known from opioid-type withdrawal syndromes. Mitragynine acts, among other things, as a partial agonist at the mu-opioid receptor. When such a receptor is regularly occupied over weeks and months, the cell adapts: the downstream cAMP signalling pathway is upregulated to compensate for the dampening. When the occupancy falls away, that counter-regulation stands unopposed. The result is an over-active nervous system.

Three mechanisms bear directly on sleep:

1. Noradrenergic overshoot. The locus coeruleus is the brain's principal source of noradrenaline and at the same time one of the nuclei most strongly dampened by opioid receptors. In withdrawal it fires markedly more. This is precisely a nucleus of the arousal system – an over-active locus coeruleus is incompatible with stable sleep.

2. REM rebound. Substances with opioid receptor activity generally suppress REM and deep sleep. When that suppression ends, the backlog effect described above sets in: unusually long and dense REM phases, unusually vivid and well-remembered dreams, frequent awakenings out of those phases. That affected individuals report strikingly vivid dreams during this period is therefore no mystery but the expected consequence of a normalisation.

3. Cortisol and the stress axis. Withdrawal states activate the hypothalamic-pituitary-adrenal axis (HPA axis). Cortisol, which normally falls to its nadir during the night and only rises again in the early hours, is then elevated at the wrong time. Cortisol is a waking signal. A level raised overnight leads to early awakening and shallow, fragmented sleep.

The time course

The acute phase of an opioid-type withdrawal usually lasts a few days to about a week. Sleep, however, often does not follow that schedule. Self-reports regularly describe physical symptoms having already subsided while difficulty falling and staying asleep continues for weeks. The specialist literature groups such longer-lasting complaints under the term protracted withdrawal syndrome; for opioid-type substances the concept is well established.

This is more than an inconvenience. Persistent lack of sleep is regarded as one of the strongest factors in relapse, because it amplifies irritability, susceptibility to stress and problems with motivation – precisely the states against which resuming use appears to be a short-term solution.

How solid is this finding?

It is the most solid part of the subject – and it still has a clear limit. Insomnia in withdrawal is documented through case reports, clinical observation and questionnaire surveys. A polysomnographic investigation actually measuring sleep stages during kratom withdrawal does not exist as matters stand. The underlying mechanisms are therefore transferred from opioid-type withdrawal syndromes, not measured in the specific case. It is a well-founded transfer – but it remains one.

What self-reports offer – and what they do not

In publicly accessible forums and in online surveys, users describe very different courses with regard to their sleep. Some of these accounts contradict one another diametrically. That is neither coincidence nor a sign of dishonesty, but the expected scatter of a data source that is not collected, not controlled and not generalisable. Five reasons for this:

Self-selection. Those who experience something striking write about it. Those who notice nothing rarely write at all. Forums depict the ends of a distribution, not its middle.
No comparison standard. Without a control group and without blinding it is impossible to separate what should be attributed to a substance from what belongs to expectation, time of day, stress level or chance.
Unknown material. The alkaloid content of plant material varies considerably with origin, harvest timing, drying and storage. Without analytical determination, two reports about the same kind of product may describe two very different compositions.
Accompanying factors. Caffeine, nicotine, alcohol, screen light, shift work and underlying conditions all act on sleep. In self-reports they are almost never recorded.
Memory is reconstructive. People are notoriously poor at estimating their own sleep duration. In sleep laboratory studies, the difference between subjectively perceived and objectively measured sleep regularly amounts to an hour or more – in both directions.

For the subject of sleep the last point carries particular weight, because it strikes at the core of the data source. Hence the rule: self-reports are an indication of what people experience and describe. They are not a measurement and not a basis for a general statement.

On the strain designations

The market terms Red Vein, Green Vein and White Vein appear regularly in these accounts. They do not denote botanical varieties of Mitragyna speciosa but trade categories relating to harvest timing and post-treatment: "Red" typically stands for a later harvest with longer or fermentative drying, "White" for an earlier harvest and shorter, often light-protected drying. That the alkaloid profile shifts measurably in the process is analytically established – fermentation and oxidation alter the ratios of the indole alkaloids present. What does not follow from this is any statement about effects. The designations are also unstandardised: what one trader calls "Red" need have nothing analytically in common with another's "Red".

Why direct research is missing – and what it would have to deliver

On the question of how kratom affects human sleep architecture, no reliable data exist. This is not an oversight; it has structural reasons.

Legal status differs considerably from country to country, which complicates multi-centre studies. Standardised test material with a declared and analytically confirmed alkaloid content is a precondition of any serious investigation and is laborious to produce for plant-based goods. Ethics committees set high hurdles for substances with dependence potential. And blinding is difficult when a substance is unmistakably recognisable by its sensory properties. To this comes a plain fact: for non-patentable plant constituents there is scarcely any commercial incentive to finance expensive clinical trials.

How a meaningful investigation would have to look can nevertheless be described clearly in methodological terms:

Method	What it captures
Polysomnography	The gold standard in the sleep laboratory: EEG, EOG, EMG, ECG, airflow and oxygen saturation simultaneously. Yields the actual distribution of sleep stages, the number of arousals and respiratory events.
Actigraphy	A wrist-worn movement sensor over several weeks. Coarser than polysomnography, but usable in everyday life and over long periods.
Validated questionnaires	For example the PSQI (Pittsburgh Sleep Quality Index) or the ISI (Insomnia Severity Index). These capture subjective experience in a comparable, analysable form.
Analysis of the test material	Quantification of mitragynine and secondary alkaloids, usually by HPLC or LC-MS/MS. Without this step no study is reproducible.

As long as these four building blocks are not brought together, every statement about kratom and sleep architecture remains a conjecture – regardless of how many people share it.

What is known about opioids in general

One area is well studied, and it is often transferred too readily. For classical opioids it is documented polysomnographically that they shift sleep architecture: the share of REM sleep and deep sleep (N3) decreases, the share of light sleep N2 increases. Under prolonged opioid therapy, sleep-related breathing disturbances have also been described, among them central sleep apnoea and irregular breathing patterns.

Transferring this to mitragynine is not permissible, for two reasons. First, mitragynine is structurally an indole alkaloid and not a morphinan – it comes from an entirely different chemical class. Second, the pharmacological literature describes it as a partial agonist at the mu-opioid receptor with a signalling preference that differs from that of classical opioids. What engages a receptor differently need not do the same thing in the whole organism. For 7-hydroxymitragynine, which shows a markedly higher affinity in receptor studies, human sleep data are entirely absent.

The honest answer is therefore: what opioids do to REM sleep is known. Whether kratom does the same is open – and it will remain open until somebody measures it.

Putting it in perspective

On kratom and sleep, exactly three things can be said at present. First: the sleep-wake rhythm is well understood, its control loops are described, and the alkaloids of Mitragyna speciosa engage none of the classical sleep switches directly – no adenosine action has been described, and serotonergic receptor interactions are so far in vitro findings. Second: insomnia after stopping prolonged regular use is documented, mechanistically well explicable, and the only consistent finding in the whole field. Third: on the question of what kratom does to a person's sleep architecture, no usable data exist – in either direction.

Anyone who keeps these three points cleanly apart has grasped the state of research in full. Everything beyond that is description – interesting, but not reliable.